20 results about "Brain Thrombus" patented technology

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.

The invention relates to application of peroxidase reductase 1 as a target spot in preparation of an IS treatment medicine, and belongs to the technical field of biological medicine. The method comprises the steps of high-sensitivity blood immune proteome map construction, large-scale independent queue longitudinal correlation verification, cross-racial and multi-tissue causal correlation verification, targeted experiment verification and mechanism exploration, target druggability evaluation, treatment potential confirmation and the like, and selects immune response proteins with significant differences between patients and controls. The immune response protein strongly related to the onset risk of the cerebral arterial thrombosis (IS) is further screened from plasma, cerebrospinal fluid and brain tissue samples, and finally the cerebral arterial thrombosis traditional Chinese medicine target peroxide reductase 1 (PRDX1) is found. A drug, such as a PRDX1 agonist or overexpression PRDX1, designed aiming at the drug target can effectively improve the progress of the IS disease.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The present invention relates to the technical field of cell therapy. Specifically disclosed are a mesenchymal stromal cell-based drug and a use thereof in the treatment of acute cerebral infarction. The present invention provides a cell-based drug, comprising mesenchymal stromal cells and a pharmaceutically acceptable excipient. Compared with stem cells, the mesenchymal stromal cells have a negative expression level of mRNA encoding self-renewal and differentiation in the mesenchymal stromal cells. The mesenchymal stromal cells account for 90% or more of the cell-based drug. The cell-based drug exhibits the characteristics and mechanism of action of stromal cells, homes to the neovasculature formed by endothelial cells at the injury site within an effective time window, plays a role in promoting / maintaining the neovasculature and remodeling the microenvironment of the injury site, fully ensures the safety and effectiveness of disease treatment, and provides a novel method for the diagnosis and treatment of related diseases.

This application relates to the fields of biomedical engineering and neuromodulation, disclosing the application of ultrashortwave in the fabrication of devices for modulating brain neural activity. The modulation of brain neural activity is achieved through the non-thermal effects of ultrashortwave, which refers to ultrashortwave with a frequency of 27.12MHz ± 0.6%, a wavelength of 11.06 nm, and a power of 1.6 ± 0.72 W. This application breaks through the traditional technical prejudice that high-frequency electric fields are unsuitable for the central nervous system, proving that non-thermal ultrashortwave can be safely used for brain neural modulation, opening up a completely new technical direction for neural modulation. With "ultrashortwave + application scenario" as its core protection element, it provides fundamental patent support for research on the treatment of various central nervous system diseases such as Parkinson's disease, stroke, depression, and Alzheimer's disease, possessing extremely high core patent value and broad clinical translation prospects.

The application relates to the field of biological medicine, and particularly discloses a fusion protein and application thereof. The fusion protein is composed of a polypeptide and six histidines, the polypeptide has sequence consistency of at least 9 / 10, 14 / 15 or 29 / 30 with the amino acid sequence shown in SEQ ID NO:1, and the six histidines are located at the C-terminal of the polypeptide. The fusion protein designed in the application is derived from a human body protein, the metabolic product is an amino acid, and therefore the safety is better than that of other therapeutic drugs. Moreover, the fusion protein can significantly reduce the infarction volume of the brain of a tMCAO model mouse, has a significant treatment on ischemic stroke, and has a longer treatment time window than that of an existing thrombolytic drug. Compared with the existing ischemic stroke treatment drug, the human sTREM2-6His fusion protein has a brand-new treatment mechanism and target.

The invention discloses a composition, a culture medium composition and a method for efficiently and stably inducing differentiation of cortical brain organoid. The composition is prepared from lithium calcium silicate, Y-27632, SB431542, LDN193189, FGF2, EGF, BDNF, NT-3 and Matrigel. According to the invention, lithium calcium silicate (LCS) is innovatively introduced as a novel bioactive material, and the cortex purity, the structural polarity, the progenitor cell maintenance and the functional maturity of the organoid can be remarkably improved through the slow-release ion effect (such as Li, Ca and SiO) of the LCS in a culture system in cooperation with a stage-specific signal channel regulation and control and a serum-free culture system. According to the invention, the brain organ with high-purity cortical characteristics, good structural texture and functional maturity can be obtained, and a new technical solution is provided for transplantation materials for cerebral arterial thrombosis disease mechanism research, drug screening evaluation and nerve regeneration treatment.

The invention discloses a chemical reprogramming multifunctional mesenchymal stromal cell based on a glycyrrhizic acid solubilizing technology and application thereof. According to the invention, a specific chemical small molecule combination is adopted, and human fibroblasts are reprogrammed into multifunctional mesenchymal stromal cells (CiMFSCs) with high expression of NSMF / NAV2 / BMP4 / LAMA2 and other genes. The key advantage of the CiMFSCs is that the CiMFSCs can target a plurality of key links of cerebral arterial thrombosis treatment at the same time, including promotion of neurogenesis, angiogenesis, repair of blood brain barrier (BBB) and exertion of paracrine function, so that effective neural function recovery is finally realized. Compared with umbilical cord mesenchymal stem cells, neural stem cells differentiated by iPSC, vascular endothelial cells differentiated by iPSC and pericytes differentiated by iPSC, the CiMFSCs show a remarkable and superior treatment effect in a stroke model mouse: the CiMFSCs can remarkably reduce the cerebral infarction volume, improve the survival rate of the model mouse, improve the neurobehavioral score and realize comprehensive repair of nerve and blood vessel units.

The invention relates to a phosphorus-containing dendrimer co-loaded fibronectin / melatonin nano-drug as well as a preparation method and application thereof. The nano-drug comprises a phosphorus-containing dendrimer ZY-135 at a hydroxyl terminal, fibronectin FN and melatonin MT. The nano-drug provided by the invention can penetrate through a blood brain barrier, accurately target a diseased region, cooperatively regulate and control microglial cells, nerve cells and vascular endothelial cells, and can realize combined treatment of oxidative stress and inflammation level alleviation, neuroprotection and vascular regeneration of cerebral arterial thrombosis, so that nerve cell apoptosis is reduced, and cerebral arterial thrombosis is reduced. Good clinical transformation prospects and application values are realized.

The application provides a method for constructing a local inflammation model of an experimental animal brain, which comprises the following steps: anesthetizing the experimental animal and fixing the experimental animal on a positioning device; injecting an immunomodulator into a target region according to the coordinates of the target region by using a puncture tool; controlling the injection speed and dose of the immunomodulator by using a micro-infusion device; keeping the puncture needle in the body for a period of time after injection to reduce the backflow of the liquid medicine; verifying the local immune activation by quantitatively detecting the expression change of an inflammation marker in the target region, and synchronously detecting the expression level of the inflammation marker in a peripheral medium to exclude a systemic immune response. The application can effectively solve the problem that the peripheral inflammation effect is difficult to distinguish in the research of brain diseases caused by systemic administration in the prior art, and can be applied to the research of the local immune activation effect of diseases such as Alzheimer's disease, ischemic stroke and glioblastoma, and the evaluation of the efficacy and mechanism of STING agonists in these diseases.

This application relates to the field of intelligent healthcare, specifically to a method, device, and program product for assessing vascular occlusion reperfusion therapy based on thrombus permeability. It includes acquiring brain images of patients with acute ischemic stroke; classifying the responsible vessel in the brain images to determine whether it is large vessel occlusion, medium vessel occlusion, or distal small vessel occlusion; when the determination result is medium vessel occlusion, thrombus region localization and measurement are performed on the brain images, thrombus permeability is calculated, and reperfusion therapy is assessed based on the thrombus permeability to obtain an assessment result for intravenous thrombolysis or endovascular therapy. This application has significant clinical application value.

The invention relates to a cerebral apoplexy treatment time window prolonging agent, application of the cerebral apoplexy treatment time window prolonging agent and a cerebral apoplexy thrombolysis kit, and the cerebral apoplexy treatment time window prolonging agent comprises a protein PAI-1 targeting inhibitor, the compound is used for being specifically combined with a plasminogen activator inhibitor PAI-1 released by activated platelets in a cerebral apoplexy thrombus area so as to inhibit the fibrinolytic inhibitory activity of the PAI-1. The invention has the beneficial effects that endogenous fibrinolysis is activated in a safe and effective way, the sharp contradiction between timeliness and safety in the prior art is directly solved, and the medicine is expected to be used as a safe early intervention medicine and provides new treatment possibility for a large number of patients who miss initial treatment opportunities. By means of the exquisite unlocking mechanism, the cerebral apoplexy treatment time window is delayed to 6 h, and precious time is gained for cerebral apoplexy treatment subsequently.

The invention relates to the field of intelligent medical treatment, in particular to a vascular occlusion reperfusion treatment evaluation method and device based on thrombus permeability and a program product. Comprising the following steps: acquiring a brain image of a patient with acute ischemic stroke; performing responsible blood vessel grading judgment on the brain image to obtain large blood vessel occlusion or medium blood vessel occlusion or far-end small blood vessel occlusion, and when the judgment result is medium blood vessel occlusion, performing thrombus area positioning and measurement on the brain image, calculating thrombus permeability, and determining the thrombus permeability. And performing reperfusion treatment evaluation through the thrombus permeability to obtain an evaluation result of intravenous thrombolysis treatment or intravascular treatment. The application has good clinical application value.

The present invention provides a compound represented by formula (I) as a USP25 inhibitor, various crystal forms, hydrates, solvates or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The USP25 inhibitor can effectively treat cerebral arterial thrombosis, especially neurological function impairment and dyskinesia caused by cerebral arterial thrombosis.

This invention provides a drug delivery system and its application based on brain microvascular endothelial cells, comprising stimulated brain microvascular endothelial cells, wherein the stimulation is performed by culturing in a culture system containing supernatant of brain microvascular endothelial cells cultured under glucose and oxygen deprivation. This invention solves the problems of targeting and timeliness in treating blood-brain barrier damage after ischemic stroke under current technologies. It can regulate the BBB while supporting its function and structure, maintaining and repairing BBB function after reperfusion, thus improving the prognosis of stroke treatment. The cell preparations in this invention are widely available and easily obtained, and can rapidly repair the blood-brain barrier. Furthermore, the cell preparations in this invention can target ischemic brain sites and can be administered via simple intravenous injection, facilitating clinical operation.

The invention discloses a TFAM-based cerebral arterial thrombosis diagnosis and prognosis evaluation kit, and relates to the technical field of medical detection, in particular to a TFAM-based cerebral arterial thrombosis diagnosis and prognosis evaluation kit, which comprises a kit body, a base, an isolation plate, a rotatable reagent rack (containing reagent tubes) arranged on one side of the isolation plate, and a liquid medicine rack (containing liquid medicine bottles) arranged on one side of the isolation plate, an elisa plate is arranged on the other side; automatic ejection of reagent tubes and liquid medicine bottles is realized through structures such as a motor, a cam and a push rod, a telescopic rod and a connecting rod mechanism control opening and closing of a reagent tube sealing cover, and an elisa plate can be driven by an ejector rod to move up and down to uniformly mix liquid in a hole; a control panel on the outer side of the box body is electrically connected with the motors and the telescopic rods, and centralized control is achieved. The kit is high in integration and automation degree, convenient to operate and suitable for rapid diagnosis and prognosis evaluation of cerebral arterial thrombosis.

The application provides an activated endothelial cell membrane-coated nanoparticle, a preparation method, application and a pharmaceutical composition, and belongs to the technical field of biomedical materials. The nanoparticle is composed of a rutin / hydroxychloroquine self-assembled nanoparticle core coated by brain microvascular endothelial cell membranes pretreated by TNF-alpha. The application screens a specific molar ratio of rutin and hydroxychloroquine. The preparation can be combined with the specific binding of ICAM-1 and integrin alpha M beta2 on the surface of neutrophils, and can be carried by neutrophils to cross the blood-brain barrier, realize parenchymal brain targeting enrichment, and synergistically exert anti-inflammatory, antioxidant, NETs formation inhibition and neuroprotective effects, thereby significantly improving ischemic stroke reperfusion injury.

This invention relates to the application of compound ID-8 in the preparation of drugs for treating ischemic cerebrovascular diseases. This invention demonstrates the protective effect of ID-8 on ischemic brain. Research data shows that ID-8 can significantly reduce brain tissue damage and cell death caused by ischemic stroke, shrink infarct foci, and improve neurological function. Compound ID-8 can be used to prepare drugs for treating ischemic cerebrovascular diseases, can be combined with various excipients, can be combined with various existing drugs for treating ischemic cerebrovascular diseases, and is applicable to various dosage forms and routes of administration. This results in novel, safe, and effective drugs and treatments for ischemic cerebrovascular diseases that can reduce brain ischemia-related damage, and has significant clinical and social value.

This invention relates to a drug for preventing ischemic stroke and its preparation method, belonging to the field of biomedical technology. It comprises 5,7,4'-trihydroxyflavone and tetramethylpyrazine in a mass ratio of (62-68):(32-38), sequentially coated with EPC-Cholesterol nanoparticles, and DSPE-PE G containing CREKA peptide and sausage pulp extract peptides. 2000 - One-time modification of complex peptides, DSPE-PEG 2000 The drug was obtained through secondary modification with TK. This invention utilizes a scientifically formulated synergistic effect of 5,7,4'-trihydroxyflavone and tetramethylpyrazine, combined with the targeting action of CREKA peptide, the protective effect of sausage pulp-extracted peptides, and DSPE-PEG. 2000 The controlled release and antioxidant effects of -TK achieve multi-level synergy of thrombus targeting, gradient controlled release, inflammation inhibition, and neuroprotection, breaking through the limitations of traditional single-component drugs and improving the effectiveness of preventing neurological damage after stroke.